Exelixis Net Worth

Exelixis Net Worth Breakdown

  EXEL
The net worth of Exelixis is the difference between its total assets and liabilities. Exelixis' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Exelixis' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Exelixis' net worth can be used as a measure of its financial health and stability which can help investors to decide if Exelixis is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Exelixis stock.

Exelixis Net Worth Analysis

Exelixis' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Exelixis' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Exelixis' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Exelixis' net worth analysis. One common approach is to calculate Exelixis' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Exelixis' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Exelixis' net worth. This approach calculates the present value of Exelixis' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Exelixis' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Exelixis' net worth. This involves comparing Exelixis' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Exelixis' net worth relative to its peers.

Enterprise Value

1.85 Billion

To determine if Exelixis is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Exelixis' net worth research are outlined below:
Exelixis has a strong financial position based on the latest SEC filings
Over 92.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Exelixis Up 13.4 percent Since Last Earnings Report Can It Continue

Exelixis Quarterly Good Will

63.68 Million

Exelixis uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Exelixis. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Exelixis' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Exelixis Target Price Consensus

Exelixis target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Exelixis' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   22  Buy
Most Exelixis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Exelixis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Exelixis, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Exelixis Target Price Projection

Exelixis' current and average target prices are 36.65 and 34.47, respectively. The current price of Exelixis is the price at which Exelixis is currently trading. On the other hand, Exelixis' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Exelixis Market Quote on 17th of March 2025

Low Price36.41Odds
High Price37.38Odds

36.65

Target Price

Analyst Consensus On Exelixis Target Price

Low Estimate31.37Odds
High Estimate38.26Odds

34.4709

Historical Lowest Forecast  31.37 Target Price  34.47 Highest Forecast  38.26
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Exelixis and the information provided on this page.

Know Exelixis' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Exelixis is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Exelixis backward and forwards among themselves. Exelixis' institutional investor refers to the entity that pools money to purchase Exelixis' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Nuveen Asset Management, Llc2024-12-31
3.5 M
Jpmorgan Chase & Co2024-12-31
3.3 M
Charles Schwab Investment Management Inc2024-12-31
3.3 M
Arrowstreet Capital Limited Partnership2024-12-31
3.2 M
Stephens Inv Mgmt Group Llc2024-12-31
3.1 M
Fmr Inc2024-12-31
2.9 M
Norges Bank2024-12-31
2.8 M
Morgan Stanley - Brokerage Accounts2024-12-31
2.8 M
First Trust Advisors L.p.2024-12-31
2.5 M
Blackrock Inc2024-12-31
30.3 M
Vanguard Group Inc2024-12-31
29.4 M
Note, although Exelixis' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Exelixis' market capitalization trends

The company currently falls under 'Large-Cap' category with a current market capitalization of 10.26 B.

Market Cap

1.81 Billion

Project Exelixis' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets 0.18  0.09 
Return On Capital Employed 0.24  0.13 
Return On Assets 0.18  0.09 
Return On Equity 0.23  0.10 
The company has Profit Margin (PM) of 0.24 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29.
When accessing Exelixis' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Exelixis' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Exelixis' profitability and make more informed investment decisions.

Evaluate Exelixis' management efficiency

Exelixis has return on total asset (ROA) of 0.1464 % which means that it generated a profit of $0.1464 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2313 %, meaning that it created $0.2313 on every $100 dollars invested by stockholders. Exelixis' management efficiency ratios could be used to measure how well Exelixis manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.09. The value of Return On Capital Employed is expected to slide to 0.13. At this time, Exelixis' Other Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 2.9 B this year, although the value of Return On Tangible Assets will most likely fall to 0.09.
Last ReportedProjected for Next Year
Book Value Per Share 7.74  7.02 
Tangible Book Value Per Share 7.52  6.82 
Enterprise Value Over EBITDA 13.67  17.18 
Price Book Value Ratio 4.39  2.60 
Enterprise Value Multiple 13.67  17.18 
Price Fair Value 4.39  2.60 
Enterprise Value1.2 B1.9 B
Exelixis benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Enterprise Value Revenue
4.3029
Revenue
2.2 B
Quarterly Revenue Growth
0.182
Revenue Per Share
7.478
Return On Equity
0.2313
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exelixis insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exelixis' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Exelixis insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Christopher Senner over a week ago
Acquisition by Christopher Senner of 29314 shares of Exelixis at 18.8 subject to Rule 16b-3
 
Smith Julie over two weeks ago
Disposition of 31167 shares by Smith Julie of Exelixis at 20.5 subject to Rule 16b-3
 
Hessekiel Jeffrey over three weeks ago
Disposition of 18134 shares by Hessekiel Jeffrey of Exelixis at 35.0 subject to Rule 16b-3
 
Haley Patrick J. over a month ago
Disposition of 27563 shares by Haley Patrick J. of Exelixis at 37.27 subject to Rule 16b-3
 
Michael Morrissey over two months ago
Disposition of 681 shares by Michael Morrissey of Exelixis at 20.99 subject to Rule 16b-3
 
Haley Patrick J. over three months ago
Disposition of 10000 shares by Haley Patrick J. of Exelixis at 35.27 subject to Rule 16b-3
 
Haley Patrick J. over three months ago
Disposition of 19381 shares by Haley Patrick J. of Exelixis at 34.41 subject to Rule 16b-3
 
Peterson Amy C. over three months ago
Disposition of 27224 shares by Peterson Amy C. of Exelixis at 35.05 subject to Rule 16b-3
 
Michael Morrissey over three months ago
Disposition of 480000 shares by Michael Morrissey of Exelixis at 24.41 subject to Rule 16b-3
 
Hessekiel Jeffrey over three months ago
Disposition of 25000 shares by Hessekiel Jeffrey of Exelixis at 26.38 subject to Rule 16b-3
 
Christopher Senner over six months ago
Disposition of 21862 shares by Christopher Senner of Exelixis at 22.86 subject to Rule 16b-3
 
Wyszomierski Jack L over six months ago
Disposition of 8287 shares by Wyszomierski Jack L of Exelixis at 22.0 subject to Rule 16b-3

Exelixis Corporate Filings

5th of March 2025
Other Reports
ViewVerify
F4
28th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
21st of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
Exelixis time-series forecasting models is one of many Exelixis' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Exelixis' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Exelixis Earnings Estimation Breakdown

The calculation of Exelixis' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Exelixis is estimated to be 0.4188 with the future projection ranging from a low of 0.29 to a high of 0.5471. Please be aware that this consensus of annual earnings estimates for Exelixis is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.55
0.29
Lowest
Expected EPS
0.4188
0.55
Highest

Exelixis Earnings Projection Consensus

Suppose the current estimates of Exelixis' value are higher than the current market price of the Exelixis stock. In this case, investors may conclude that Exelixis is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Exelixis' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2025Current EPS (TTM)
2276.08%
0.55
0.4188
1.76

Exelixis Earnings History

Earnings estimate consensus by Exelixis analysts from Wall Street is used by the market to judge Exelixis' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Exelixis' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Exelixis Quarterly Gross Profit

546.79 Million

At this time, Exelixis' Price Earnings Ratio is quite stable compared to the past year. Price Earnings To Growth Ratio is expected to rise to 0.24 this year, although the value of Retained Earnings will most likely fall to (103.6 M). Net Income Applicable To Common Shares is expected to rise to about 220.1 M this year, although the value of Common Stock Shares Outstanding will most likely fall to about 183.9 M.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Exelixis' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
34.3236.7439.16
Details
Intrinsic
Valuation
LowRealHigh
32.9335.3537.77
Details
Naive
Forecast
LowNextHigh
30.7333.1535.56
Details
22 Analysts
Consensus
LowTargetHigh
31.3734.4738.26
Details
Note that many institutional investors and large investment bankers can move markets due to the volume of Exelixis assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Exelixis. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Exelixis' stock price in the short term.

Exelixis Earnings per Share Projection vs Actual

Actual Earning per Share of Exelixis refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Exelixis predict the company's earnings will be in the future. The higher the earnings per share of Exelixis, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Exelixis Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Exelixis, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Exelixis should always be considered in relation to other companies to make a more educated investment decision.

Exelixis Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Exelixis' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-02-04
2024-12-310.49180.550.058211 
2024-10-29
2024-09-300.350.40.0514 
2024-08-06
2024-06-300.30.770.47156 
2024-04-30
2024-03-310.240.2-0.0416 
2024-02-06
2023-12-310.210.270.0628 
2023-11-01
2023-09-300.10.10.0
2023-08-01
2023-06-300.160.250.0956 
2023-05-09
2023-03-310.150.12-0.0320 
2023-02-07
2022-12-31-0.12-0.090.0325 
2022-11-01
2022-09-300.190.230.0421 
2022-08-09
2022-06-300.190.220.0315 
2022-05-10
2022-03-310.140.210.0750 
2022-02-17
2021-12-310.060.290.23383 
2021-11-02
2021-09-300.170.12-0.0529 
2021-08-05
2021-06-300.060.30.24400 
2021-05-06
2021-03-310.030.005-0.02583 
2021-02-10
2020-12-310.050.090.0480 
2020-11-05
2020-09-300.01-0.1-0.111100 
2020-08-06
2020-06-300.120.210.0975 
2020-05-05
2020-03-310.130.150.0215 
2020-02-25
2019-12-310.170.220.0529 
2019-10-30
2019-09-300.190.310.1263 
2019-07-31
2019-06-300.230.250.02
2019-05-01
2019-03-310.230.240.01
2019-02-12
2018-12-310.230.370.1460 
2018-11-01
2018-09-300.190.410.22115 
2018-08-01
2018-06-300.160.280.1275 
2018-05-02
2018-03-310.160.370.21131 
2018-02-26
2017-12-310.120.120.0
2017-11-01
2017-09-300.080.260.18225 
2017-08-02
2017-06-300.040.060.0250 
2017-05-01
2017-03-31-0.010.050.06600 
2017-02-27
2016-12-31-0.010.120.131300 
2016-11-03
2016-09-30-0.11-0.040.0763 
2016-08-03
2016-06-30-0.27-0.160.1140 
2016-05-04
2016-03-31-0.25-0.27-0.02
2016-02-29
2015-12-31-0.22-0.190.0313 
2015-11-10
2015-09-30-0.2-0.22-0.0210 
2015-08-11
2015-06-30-0.21-0.22-0.01
2015-04-30
2015-03-31-0.24-0.180.0625 
2015-02-24
2014-12-31-0.3-0.30.0
2014-11-04
2014-09-30-0.37-0.320.0513 
2014-07-31
2014-06-30-0.39-0.380.01
2014-05-01
2014-03-31-0.37-0.39-0.02
2014-02-20
2013-12-31-0.38-0.380.0
2013-10-30
2013-09-30-0.37-0.360.01
2013-08-06
2013-06-30-0.3-0.34-0.0413 
2013-05-07
2013-03-31-0.28-0.240.0414 
2013-02-21
2012-12-31-0.24-0.28-0.0416 
2012-11-07
2012-09-30-0.3-0.20.133 
2012-08-02
2012-06-30-0.27-0.250.02
2012-05-03
2012-03-31-0.17-0.18-0.01
2012-02-08
2011-12-31-0.110.350.46418 
2011-10-27
2011-09-300.560.590.03
2011-08-04
2011-06-30-0.17-0.160.01
2011-05-03
2011-03-31-0.19-0.24-0.0526 
2011-02-22
2010-12-31-0.2-0.160.0420 
2010-11-04
2010-09-30-0.05-0.08-0.0360 
2010-08-05
2010-06-30-0.21-0.210.0
2010-05-11
2010-03-31-0.31-0.4-0.0929 
2010-03-09
2009-12-31-0.27-0.270.0
2009-10-29
2009-09-30-0.32-0.240.0825 
2009-07-30
2009-06-30-0.41-0.42-0.01
2009-05-07
2009-03-31-0.33-0.34-0.01
2009-03-04
2008-12-31-0.35-0.36-0.01
2008-10-27
2008-09-30-0.41-0.360.0512 
2008-08-05
2008-06-30-0.41-0.43-0.02
2008-05-06
2008-03-31-0.38-0.39-0.01
2008-02-14
2007-12-31-0.29-0.190.134 
2007-11-05
2007-09-30-0.19-0.140.0526 
2007-08-07
2007-06-30-0.28-0.29-0.01
2007-05-03
2007-03-31-0.27-0.250.02
2007-02-13
2006-12-31-0.25-0.27-0.02
2006-11-02
2006-09-30-0.31-0.30.01
2006-08-08
2006-06-30-0.3-0.290.01
2006-05-09
2006-03-31-0.29-0.32-0.0310 
2006-02-21
2005-12-31-0.28-0.29-0.01
2005-11-03
2005-09-30-0.39-0.280.1128 
2005-08-08
2005-06-30-0.05-0.13-0.08160 
2005-05-09
2005-03-31-0.36-0.360.0
2005-02-16
2004-12-31-0.38-0.350.03
2004-11-08
2004-09-30-0.42-0.370.0511 
2004-08-05
2004-06-30-0.38-0.370.01
2004-05-04
2004-03-31-0.41-0.390.02
2004-02-17
2003-12-31-0.35-0.320.03
2003-11-05
2003-09-30-0.38-0.340.0410 
2003-08-06
2003-06-30-0.42-0.40.02
2003-05-07
2003-03-31-0.41-0.380.03
2003-02-19
2002-12-31-0.4-0.340.0615 
2002-11-07
2002-09-30-0.42-0.390.03
2002-08-06
2002-06-30-0.41-0.390.02
2002-05-06
2002-03-31-0.31-0.310.0
2002-03-20
2001-12-31-0.32-0.260.0618 
2001-11-13
2001-09-30-0.31-0.280.03
2001-08-08
2001-06-30-0.31-0.30.01
2001-05-14
2001-03-31-0.26-0.220.0415 
2001-02-28
2000-12-31-0.2-0.180.0210 
2000-11-08
2000-09-30-0.13-0.130.0
2000-08-08
2000-06-30-0.13-0.16-0.0323 

Exelixis Corporate Management

Amy MDProduct VPProfile
Laura DillardExecutive ResourcesProfile
Tony RedmondSenior ResourcesProfile
Gregg BernierVP MarketingProfile
William MDSenior AffairsProfile
When determining whether Exelixis is a strong investment it is important to analyze Exelixis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Exelixis' future performance. For an informed investment choice regarding Exelixis Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.754
Earnings Share
1.76
Revenue Per Share
7.478
Quarterly Revenue Growth
0.182
Return On Assets
0.1464
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.